FDA Approves Drug That Can Delay Onset of Type 1 Diabetes
November 17, 2022
The FDA approved Tzield® (teplizumab-mzwv) injection, a new drug that can delay the onset of type 1 diabetes by several months or years. Type 1 diabetes occurs when the immune system attacks and destroys the cells that make insulin, requiring individuals to check their blood sugar regularly and deliver insulin shots to survive. Tzield deactivates the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the immune system. Tzield must be delivered intravenously once daily for 14 consecutive days.